Earnings per Share (EPS) Prediction: Wall Street analysts forecast an EPS of -$2.92, marking a 4.9% improvement year-over-year despite expected revenue decline.
Revenue Decline: Anticipated revenue of $115.3 million, a 24% decrease, primarily due to reduced demand for Moderna’s COVID-19 vaccine.
Financial Metrics and Ratios: Moderna faces challenges with a negative P/E ratio of -3.02 and a strong current ratio of 3.67.
Moderna Inc. (NASDAQ: MRNA) is a biotechnology company known for its mRNA technology, which played a crucial role in developing its COVID-19 vaccine. As the company prepares to release its quarterly earnings on May 1, 2025, Wall Street analysts predict an earnings per share (EPS) of -$2.92. This represents a 4.9% improvement from the previous year, despite a projected revenue decline of 24% to $115.3 million.
The anticipated revenue decline is primarily due to reduced demand for Moderna’s COVID-19 vaccine, with expected sales of $112 million. This decrease is significant compared to previous years when the vaccine was in high demand. Additionally, the company’s RSV vaccine, mResvia, is expected to contribute minimally to sales, with an estimated $10 million. Investors will be keen to hear updates on Moderna’s pipeline during the earnings report.
Over the past month, analysts have slightly adjusted the consensus EPS estimate downward by 0.1%. These revisions are important as they can influence investor reactions and short-term stock price movements. In the previous quarter, Moderna exceeded earnings estimates by 7.06%, but there is concern that the company may not achieve an earnings beat this time. The Zacks Consensus Estimate predicts a quarterly loss of $2.91 per share.
Moderna’s financial metrics reveal some challenges. The company has a negative price-to-earnings (P/E) ratio of -3.02, indicating negative earnings. The price-to-sales ratio is about 3.34, suggesting investors are willing to pay $3.34 for every dollar of sales. The enterprise value to sales ratio is approximately 2.96, providing insight into the company’s valuation relative to its revenue.
Despite these challenges, Moderna maintains a strong current ratio of about 3.67, indicating a solid ability to cover short-term liabilities with short-term assets. The debt-to-equity ratio is relatively low at 0.065, reflecting a conservative approach to leveraging debt. Investors will closely monitor the earnings call for management’s discussion on the sustainability of any immediate price changes and future earnings expectations.
